Skip to main content
Erschienen in: coloproctology 5/2016

08.12.2015 | Update

Chronisch-entzündliche Darmerkrankungen

Wissenschaft heute – Standard morgen, Koloproktologie UPDATE 2015

verfasst von: Prof. Dr. T. Andus

Erschienen in: coloproctology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Auszug

Auch im letzten Jahr wurden wieder mehrere Tausend Arbeiten zum Thema „chronisch-entzündliche Darmerkrankungen“ publiziert. Die Auswahl erfolgte nach den Kriterien „Klinische Relevanz“ und „Neuigkeitswert“. Ich hoffe, für die Leser eine interessante Auswahl getroffen zu haben. …
Literatur
1.
Zurück zum Zitat Dignass A, Preiss JC, Aust DE, Autschbach F, Ballauff A, Barretton G, Bokemeyer B, Fichtner-Feigl S, Hagel S, Herrlinger KR, Jantschek G, Kroesen A, Kruis W, Kucharzik T, Langhorst J, Reinshagen M, Rogler G, Schleiermacher D, Schmidt C, Schreiber S, Schulze H, Stange E, Zeitz M, Hoffmann JC, Stallmach A (2011) Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011. Z Gastroenterol 49(9):1276–1341CrossRefPubMed Dignass A, Preiss JC, Aust DE, Autschbach F, Ballauff A, Barretton G, Bokemeyer B, Fichtner-Feigl S, Hagel S, Herrlinger KR, Jantschek G, Kroesen A, Kruis W, Kucharzik T, Langhorst J, Reinshagen M, Rogler G, Schleiermacher D, Schmidt C, Schreiber S, Schulze H, Stange E, Zeitz M, Hoffmann JC, Stallmach A (2011) Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011. Z Gastroenterol 49(9):1276–1341CrossRefPubMed
2.
Zurück zum Zitat Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, Van Assche G (2012) Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 6(10):965–990CrossRefPubMed Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, Van Assche G (2012) Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 6(10):965–990CrossRefPubMed
3.
Zurück zum Zitat Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D’Haens G, D’Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G (2012) Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 6(10):991–1030CrossRefPubMed Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D’Haens G, D’Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G (2012) Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 6(10):991–1030CrossRefPubMed
4.
Zurück zum Zitat Van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollón F, Häuser W, Herrlinger K, Oldenburg B, Panes J, Portela F, Rogler G, Stein J, Tilg H, Travis S, Lindsay JO, European Crohn’s and Colitis Organisation (2013) Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 7(1):1–33CrossRefPubMed Van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollón F, Häuser W, Herrlinger K, Oldenburg B, Panes J, Portela F, Rogler G, Stein J, Tilg H, Travis S, Lindsay JO, European Crohn’s and Colitis Organisation (2013) Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 7(1):1–33CrossRefPubMed
6.
Zurück zum Zitat Nguyen GC, Bernstein CN, Bitton A, Chan AK, Griffiths AM, Leontiadis GI, Geerts W, Bressler B, Butzner JD, Carrier M, Chande N, Marshall JK, Williams C (2014) Kearon C Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology 146(3):835–848CrossRefPubMed Nguyen GC, Bernstein CN, Bitton A, Chan AK, Griffiths AM, Leontiadis GI, Geerts W, Bressler B, Butzner JD, Carrier M, Chande N, Marshall JK, Williams C (2014) Kearon C Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology 146(3):835–848CrossRefPubMed
7.
Zurück zum Zitat Ananthakrishnan AN, Cagan A, Gainer VS, Cheng SC, Cai T, Scoville E, Konijeti GG, Szolovits P, Shaw SY, Churchill S, Karlson EW, Murphy SN, Kohane I, Liao KP (2014) Thromboprophylaxis is associated with reduced post-hospitalization venous thromboembolic events in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 12(11):1905–1910CrossRefPubMedPubMedCentral Ananthakrishnan AN, Cagan A, Gainer VS, Cheng SC, Cai T, Scoville E, Konijeti GG, Szolovits P, Shaw SY, Churchill S, Karlson EW, Murphy SN, Kohane I, Liao KP (2014) Thromboprophylaxis is associated with reduced post-hospitalization venous thromboembolic events in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 12(11):1905–1910CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Nørgård BM, Nielsen J, Qvist N, Gradel KO, de Muckadell OB, Kjeldsen J (2012) Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis – a nationwide cohort study. Aliment Pharmacol Ther 35(11):1301–1309CrossRefPubMed Nørgård BM, Nielsen J, Qvist N, Gradel KO, de Muckadell OB, Kjeldsen J (2012) Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis – a nationwide cohort study. Aliment Pharmacol Ther 35(11):1301–1309CrossRefPubMed
9.
Zurück zum Zitat Billioud V, Ford AC, Tedesco ED, Colombel JF, Roblin X, Peyrin-Biroulet L (2013) Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. J Crohns Colitis 7(11):853–867CrossRefPubMed Billioud V, Ford AC, Tedesco ED, Colombel JF, Roblin X, Peyrin-Biroulet L (2013) Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. J Crohns Colitis 7(11):853–867CrossRefPubMed
10.
Zurück zum Zitat Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP (2005) Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut 54(2):237–241CrossRefPubMedPubMedCentral Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP (2005) Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut 54(2):237–241CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Kaplan GG, Seow CH, Ghosh S, Molodecky N, Rezaie A, Moran GW, Proulx MC, Hubbard J, MacLean A, Buie D, Panaccione R (2012) Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol 107(12):1879–1887CrossRefPubMed Kaplan GG, Seow CH, Ghosh S, Molodecky N, Rezaie A, Moran GW, Proulx MC, Hubbard J, MacLean A, Buie D, Panaccione R (2012) Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol 107(12):1879–1887CrossRefPubMed
12.
Zurück zum Zitat Chatu S, Saxena S, Subramanian V, Curcin V, Yadegarfar G, Gunn L, Majeed A, Pollok RC (2014) The impact of timing and duration of thiopurine treatment on first intestinal resection in Crohn’s disease: national UK population-based study 1989–2010. Am J Gastroenterol 109(3):409–416CrossRefPubMed Chatu S, Saxena S, Subramanian V, Curcin V, Yadegarfar G, Gunn L, Majeed A, Pollok RC (2014) The impact of timing and duration of thiopurine treatment on first intestinal resection in Crohn’s disease: national UK population-based study 1989–2010. Am J Gastroenterol 109(3):409–416CrossRefPubMed
13.
Zurück zum Zitat Frøslie KF, Jahnsen J, Moum BA, Moum BA, IBSEN Group (2007) Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133(2):412–422CrossRefPubMed Frøslie KF, Jahnsen J, Moum BA, Moum BA, IBSEN Group (2007) Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133(2):412–422CrossRefPubMed
14.
Zurück zum Zitat Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ (2011) Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 141(4):1194–1201CrossRefPubMed Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ (2011) Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 141(4):1194–1201CrossRefPubMed
15.
Zurück zum Zitat Ehehalt R, Braun A, Karner M, Füllekrug J, Stremmel W (2010) Phosphatidylcholine as a constituent in the colonic mucosal barrier – physiological and clinical relevance. Biochim Biophys Acta 1801(9):983–993CrossRefPubMed Ehehalt R, Braun A, Karner M, Füllekrug J, Stremmel W (2010) Phosphatidylcholine as a constituent in the colonic mucosal barrier – physiological and clinical relevance. Biochim Biophys Acta 1801(9):983–993CrossRefPubMed
16.
Zurück zum Zitat Stremmel W, Hanemann A, Ehehalt R, Karner M, Braun A (2010) Phosphatidylcholine (lecithin) and the mucus layer: Evidence of therapeutic efficacy in ulcerative colitis? Dig Dis 28(3):490–496CrossRefPubMed Stremmel W, Hanemann A, Ehehalt R, Karner M, Braun A (2010) Phosphatidylcholine (lecithin) and the mucus layer: Evidence of therapeutic efficacy in ulcerative colitis? Dig Dis 28(3):490–496CrossRefPubMed
17.
Zurück zum Zitat Stremmel W, Gauss A (2013) Lecithin as a therapeutic agent in ulcerative colitis. Dig Dis 31(3–4):388–390CrossRefPubMed Stremmel W, Gauss A (2013) Lecithin as a therapeutic agent in ulcerative colitis. Dig Dis 31(3–4):388–390CrossRefPubMed
18.
Zurück zum Zitat Hicks CW, Hodin RA, Bordeianou L (2013) Possible overuse of 3-stage procedures for active ulcerative colitis. JAMA Surg 148(7):658–664CrossRefPubMed Hicks CW, Hodin RA, Bordeianou L (2013) Possible overuse of 3-stage procedures for active ulcerative colitis. JAMA Surg 148(7):658–664CrossRefPubMed
19.
Zurück zum Zitat Bikhchandani J, Polites SF, Wagie AE, Habermann EB, Cima RR (2015) National trends of 3- versus 2-stage restorative proctocolectomy for chronic ulcerative colitis. Dis Colon Rectum 58(2):199–204CrossRefPubMed Bikhchandani J, Polites SF, Wagie AE, Habermann EB, Cima RR (2015) National trends of 3- versus 2-stage restorative proctocolectomy for chronic ulcerative colitis. Dis Colon Rectum 58(2):199–204CrossRefPubMed
20.
Zurück zum Zitat Cohan JN, Bacchetti P, Varma MG, Finlayson E (2015) Impact of Patient Age on Procedure Type for Ulcerative Colitis: A National Study. Dis Colon Rectum 58(8):769–774CrossRefPubMed Cohan JN, Bacchetti P, Varma MG, Finlayson E (2015) Impact of Patient Age on Procedure Type for Ulcerative Colitis: A National Study. Dis Colon Rectum 58(8):769–774CrossRefPubMed
21.
Zurück zum Zitat Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB (2010) Natural history of Crohn’s disease in a population-based cohort from Cardiff (1986–2003): a study of changes in medical treatment and surgical resection rates. Gut 59(9):1200–1206CrossRefPubMed Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB (2010) Natural history of Crohn’s disease in a population-based cohort from Cardiff (1986–2003): a study of changes in medical treatment and surgical resection rates. Gut 59(9):1200–1206CrossRefPubMed
22.
Zurück zum Zitat Panés J, López-Sanromán A, Bermejo F, García-Sánchez V, Esteve M, Torres Y, Domènech E, Piqueras M, Gomez-García M, Gutiérrez A, Taxonera C, Sans M, AZTEC Study Group (2013) Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology 145(4):766–774CrossRefPubMed Panés J, López-Sanromán A, Bermejo F, García-Sánchez V, Esteve M, Torres Y, Domènech E, Piqueras M, Gomez-García M, Gutiérrez A, Taxonera C, Sans M, AZTEC Study Group (2013) Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology 145(4):766–774CrossRefPubMed
23.
Zurück zum Zitat Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F, Allez M, Dupas JL, Reimund JM, Savoye G, Jouet P, Moreau J, Mary JY, Colombel JF (2013) Groupe d’Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Early administration of azathioprine vs conventional management of Crohn’s Disease: a randomized controlled trial. Gastroenterology 145(4):758–765CrossRefPubMed Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F, Allez M, Dupas JL, Reimund JM, Savoye G, Jouet P, Moreau J, Mary JY, Colombel JF (2013) Groupe d’Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Early administration of azathioprine vs conventional management of Crohn’s Disease: a randomized controlled trial. Gastroenterology 145(4):758–765CrossRefPubMed
24.
Zurück zum Zitat Chhaya V, Saxena S, Cecil E, Subramanian V, Curcin V, Majeed A, Pollok RC (2015) Impact of timing and duration of thiopurine treatment on first perianal surgery in Crohn’s disease: UK population-based study (1995–2009). Inflamm Bowel Dis 21(2):385–391CrossRefPubMed Chhaya V, Saxena S, Cecil E, Subramanian V, Curcin V, Majeed A, Pollok RC (2015) Impact of timing and duration of thiopurine treatment on first perianal surgery in Crohn’s disease: UK population-based study (1995–2009). Inflamm Bowel Dis 21(2):385–391CrossRefPubMed
25.
Zurück zum Zitat Szamosi T, Banai J, Lakatos L, Czegledi Z, David G, Zsigmond F, Pandur T, Erdelyi Z, Gemela O, Papp M, Papp J, Lakatos PL (2010) Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn’s disease, while smoking decreases the risk of colectomy in ulcerative colitis. Eur J Gastroenterol Hepatol 22(7):872–879CrossRefPubMed Szamosi T, Banai J, Lakatos L, Czegledi Z, David G, Zsigmond F, Pandur T, Erdelyi Z, Gemela O, Papp M, Papp J, Lakatos PL (2010) Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn’s disease, while smoking decreases the risk of colectomy in ulcerative colitis. Eur J Gastroenterol Hepatol 22(7):872–879CrossRefPubMed
26.
Zurück zum Zitat Walters TD, Kim MO, Denson LA, Griffiths AM, Dubinsky M, Markowitz J, Baldassano R, Crandall W, Rosh J, Pfefferkorn M, Otley A, Heyman MB, LeLeiko N, Baker S, Guthery SL, Evans J, Ziring D, Kellermayer R, Stephens M, Mack D, Oliva-Hemker M, Patel AS, Kirschner B, Moulton D, Cohen S, Kim S, Liu C, Essers J, Kugathasan S, Hyams JS, PRO-KIIDS Research Group (2014) Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn’s disease. Gastroenterology 146(2):383–391CrossRefPubMed Walters TD, Kim MO, Denson LA, Griffiths AM, Dubinsky M, Markowitz J, Baldassano R, Crandall W, Rosh J, Pfefferkorn M, Otley A, Heyman MB, LeLeiko N, Baker S, Guthery SL, Evans J, Ziring D, Kellermayer R, Stephens M, Mack D, Oliva-Hemker M, Patel AS, Kirschner B, Moulton D, Cohen S, Kim S, Liu C, Essers J, Kugathasan S, Hyams JS, PRO-KIIDS Research Group (2014) Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn’s disease. Gastroenterology 146(2):383–391CrossRefPubMed
27.
Zurück zum Zitat Camus M, Seksik P, Bourrier A, Nion-Larmurier I, Sokol H, Baumer P, Beaugerie L, Cosnes J (2013) Long-term outcome of patients with Crohn’s disease who respond to azathioprine. Clin Gastroenterol Hepatol 11(4):389–394CrossRefPubMed Camus M, Seksik P, Bourrier A, Nion-Larmurier I, Sokol H, Baumer P, Beaugerie L, Cosnes J (2013) Long-term outcome of patients with Crohn’s disease who respond to azathioprine. Clin Gastroenterol Hepatol 11(4):389–394CrossRefPubMed
28.
Zurück zum Zitat De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Jakobovits S, Florin TH, Gibson PR, Debinski H, Gearry RB, Macrae FA, Leong RW, Kronborg I, Radford-Smith G, Selby W, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Desmond PV (2015) Efficacy of thiopurines and adalimumab in preventing Crohn’s disease recurrence in high-risk patients – a POCER study analysis. Aliment Pharmacol Ther 42(7):867–879CrossRefPubMed De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Jakobovits S, Florin TH, Gibson PR, Debinski H, Gearry RB, Macrae FA, Leong RW, Kronborg I, Radford-Smith G, Selby W, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Desmond PV (2015) Efficacy of thiopurines and adalimumab in preventing Crohn’s disease recurrence in high-risk patients – a POCER study analysis. Aliment Pharmacol Ther 42(7):867–879CrossRefPubMed
29.
Zurück zum Zitat Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Krejany EO, Leach S, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Jakobovits SL, Florin TH, Gibson PR, Debinski H, Macrae FA, Samuel D, Kronborg I, Radford-Smith G, Selby W, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Day AS, Desmond PV, Gearry RB (2015) Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn’s disease after surgery. Gastroenterology 148(5):938–947CrossRefPubMed Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Krejany EO, Leach S, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Jakobovits SL, Florin TH, Gibson PR, Debinski H, Macrae FA, Samuel D, Kronborg I, Radford-Smith G, Selby W, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Day AS, Desmond PV, Gearry RB (2015) Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn’s disease after surgery. Gastroenterology 148(5):938–947CrossRefPubMed
30.
Zurück zum Zitat Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, Rutgeerts P, Tang LK, Cornillie FJ, Sandborn WJ (2014) Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut 63(1):88–95CrossRefPubMed Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, Rutgeerts P, Tang LK, Cornillie FJ, Sandborn WJ (2014) Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut 63(1):88–95CrossRefPubMed
31.
Zurück zum Zitat Colombel JF, Reinisch W, Mantzaris GJ, Kornbluth A, Rutgeerts P, Tang KL, Oortwijn A, Bevelander GS, Cornillie FJ, Sandborn WJ (2015) Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn’s disease – a SONIC post hoc analysis. Aliment Pharmacol Ther 41(8):734–746CrossRefPubMed Colombel JF, Reinisch W, Mantzaris GJ, Kornbluth A, Rutgeerts P, Tang KL, Oortwijn A, Bevelander GS, Cornillie FJ, Sandborn WJ (2015) Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn’s disease – a SONIC post hoc analysis. Aliment Pharmacol Ther 41(8):734–746CrossRefPubMed
32.
Zurück zum Zitat Bouguen G, Sninsky C, Tang KL, Colombel JF, D’Haens G, Kornbluth A, Mantzaris GJ, Rachmilewitz D, Reinisch W, Rutgeerts P, Molenda M, der Jannekevan WC, Sandborn WJ (2015) Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC. Inflamm Bowel Dis 21(3):606–614CrossRefPubMed Bouguen G, Sninsky C, Tang KL, Colombel JF, D’Haens G, Kornbluth A, Mantzaris GJ, Rachmilewitz D, Reinisch W, Rutgeerts P, Molenda M, der Jannekevan WC, Sandborn WJ (2015) Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC. Inflamm Bowel Dis 21(3):606–614CrossRefPubMed
33.
Zurück zum Zitat Hoffmann JC, Preiss JC, Autschbach F, Buhr HJ, Häuser W, Herrlinger K, Höhne W, Koletzko S, Krieglstein CF, Kruis W, Matthes H, Moser G, Reinshagen M, Rogler G, Schreiber S, Schreyer AG, Sido B, Siegmund B, Stallmach A, Bokemeyer B, Stange EF, Zeitz M (2008) Clinical practice guideline on diagnosis and treatment of Crohn’s disease. Z Gastroenterol 46(9):1094–1146CrossRefPubMed Hoffmann JC, Preiss JC, Autschbach F, Buhr HJ, Häuser W, Herrlinger K, Höhne W, Koletzko S, Krieglstein CF, Kruis W, Matthes H, Moser G, Reinshagen M, Rogler G, Schreiber S, Schreyer AG, Sido B, Siegmund B, Stallmach A, Bokemeyer B, Stange EF, Zeitz M (2008) Clinical practice guideline on diagnosis and treatment of Crohn’s disease. Z Gastroenterol 46(9):1094–1146CrossRefPubMed
34.
Zurück zum Zitat Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, Guslandi M, Oldenburg B, Dotan I, Marteau P, Ardizzone A, Baumgart DC, D’Haens G, Gionchetti P, Portela F, Vucelic B, Söderholm J, Escher J, Koletzko S, Kolho KL, Lukas M, Mottet C, Tilg H, Vermeire S, Carbonnel F, Cole A, Novacek G, Reinshagen M, Tsianos E, Herrlinger K, Oldenburg B, Bouhnik Y, Kiesslich R, Stange E, Travis S, Lindsay J, European Crohn’s and Colitis Organisation (ECCO) (2010) The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Special situations. J Crohns Colitis 4(1):63–101CrossRefPubMed Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, Guslandi M, Oldenburg B, Dotan I, Marteau P, Ardizzone A, Baumgart DC, D’Haens G, Gionchetti P, Portela F, Vucelic B, Söderholm J, Escher J, Koletzko S, Kolho KL, Lukas M, Mottet C, Tilg H, Vermeire S, Carbonnel F, Cole A, Novacek G, Reinshagen M, Tsianos E, Herrlinger K, Oldenburg B, Bouhnik Y, Kiesslich R, Stange E, Travis S, Lindsay J, European Crohn’s and Colitis Organisation (ECCO) (2010) The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Special situations. J Crohns Colitis 4(1):63–101CrossRefPubMed
35.
Zurück zum Zitat Rogler G (2014) Crohn’s disease: Fistulising disease – a problem shared is a problem halved? Nat Rev Gastroenterol Hepatol 11(10):581–583PubMed Rogler G (2014) Crohn’s disease: Fistulising disease – a problem shared is a problem halved? Nat Rev Gastroenterol Hepatol 11(10):581–583PubMed
36.
Zurück zum Zitat Parikh A, Fox I, Leach T, Xu J, Scholz C, Patella M, Feagan BG (2013) Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis 19(8):1691–1699CrossRefPubMed Parikh A, Fox I, Leach T, Xu J, Scholz C, Patella M, Feagan BG (2013) Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis 19(8):1691–1699CrossRefPubMed
37.
Zurück zum Zitat Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D’Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S (2014) Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 147(3):618–627CrossRefPubMed Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D’Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S (2014) Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 147(3):618–627CrossRefPubMed
38.
Zurück zum Zitat Shelton E, Allegretti JR, Stevens B, Lucci M, Khalili H, Nguyen DD, Sauk J, Giallourakis C, Garber J, Hamilton MJ, Tomczak M, Makrauer F, Burakoff RB, Levine J, de Silva P, Friedman S, Ananthakrishnan A, Korzenik JR, Yajnik V (2015) Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. Inflamm Bowel Dis 21(12):2879–2885CrossRefPubMed Shelton E, Allegretti JR, Stevens B, Lucci M, Khalili H, Nguyen DD, Sauk J, Giallourakis C, Garber J, Hamilton MJ, Tomczak M, Makrauer F, Burakoff RB, Levine J, de Silva P, Friedman S, Ananthakrishnan A, Korzenik JR, Yajnik V (2015) Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. Inflamm Bowel Dis 21(12):2879–2885CrossRefPubMed
Metadaten
Titel
Chronisch-entzündliche Darmerkrankungen
Wissenschaft heute – Standard morgen, Koloproktologie UPDATE 2015
verfasst von
Prof. Dr. T. Andus
Publikationsdatum
08.12.2015
Verlag
Springer Medizin
Erschienen in
coloproctology / Ausgabe 5/2016
Print ISSN: 0174-2442
Elektronische ISSN: 1615-6730
DOI
https://doi.org/10.1007/s00053-015-0064-1

Weitere Artikel der Ausgabe 5/2016

coloproctology 5/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.